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ABSTRACT: The enabling technologies of synthetic biology
are opening up new opportunities for engineering and
enhancement of mammalian cells. This will stimulate diverse
applications in many life science sectors such as regenerative
medicine, development of biosensing cell lines, therapeutic
protein production, and generation of new synthetic genetic
regulatory circuits. Harnessing the full potential of these new
engineering-based approaches requires the design and
assembly of large DNA constructspotentially up to
chromosome scaleand the effective delivery of these large
DNA payloads to the host cell. Random integration of large
transgenes, encoding therapeutic proteins or genetic circuits
into host chromosomes, has several drawbacks such as risks of
insertional mutagenesis, lack of control over transgene copy-number and position-specific effects; these can compromise the
intended functioning of genetic circuits. The development of a system orthogonal to the endogenous genome is therefore
beneficial. Mammalian artificial chromosomes (MACs) are functional, add-on chromosomal elements, which behave as normal
chromosomesbeing replicating and portioned to daughter cells at each cell division. They are deployed as useful gene
expression vectors as they remain independent from the host genome. MACs are maintained as a single-copy and can
accommodate multiple gene expression cassettes of, in theory, unlimited DNA size (MACs up to 10 megabases have been
constructed). MACs therefore enabled control over ectopic gene expression and represent an excellent platform to rapidly
prototype and characterize novel synthetic gene circuits without recourse to engineering the host genome. This review describes
the obstacles synthetic biologists face when working with mammalian systems and how the development of improved MACs can
overcome theseparticularly given the spectacular advances in DNA synthesis and assembly that are fuelling this research area.
KEYWORDS: mammalian synthetic biology, artificial chromosome, chromosome engineering
Synthetic biology is an emerging area of research whosemain aim is the design, construction and characterization of
synthetic genetic circuits that once integrated into the cellular
host produce desirable outputs in a robust and predictable
manner.1−3 In recent years, synthetic biology applied to
mammalian cells has rapidly evolved and achieved impressive
advancements and proof-of-principle studies for the generation
of complex and diverse genetic devices.1−3 Several functional
genetic modules such as toggle switches,4 boolean logic gates,5
hysteretic switches,6 oscillators7 and light induced optogenetic
switches8 have been successfully developed in mammalian cells.
It is now essential to generate more complex and therapy-
oriented gene circuits, assembling modules into larger scale
systems that are robust and predictable. This essential step will
help synthetic biologists design and generate genetic circuits
resembling the intriguing complexities of the native mammalian
gene regulatory networks, allowing higher and finer grained of
control over the cell behavior.
In this review, we will first discuss the issues of scalability,
orthogonality and predictability that must be addressed for the
implementation of more complex synthetic genetic circuits in
mammalian systems. We go on to outline and discuss how the
exploitation of mammalian artificial chromosomes (MACs) as
delivery vehicles for transgenes and circuits might help tackle
some of these issues.
■ CHALLENGES OF SYNTHETIC BIOLOGY IN
MAMMALIAN SYSTEMS
Genetic engineering has traditionally been limited to small-scale
locus-specific or random changes aimed in a gene-centric
manner, rather than enhancement or delivery of novel synthetic
genetic circuits with multiple parts and control elements.
Synthetic biology, on the other hand, brings engineering
principles to biotechnology (i.e., standardization, decoupling,
abstraction and reusability) allowing a faster, more predictable,
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reproducible and ultimately cheaper ways to engineer living
materials.9 Synthetic biology has therefore been regarded as a
genetic engineering in overdrive enabling, through advances in
de novo DNA synthesis and DNA assembly,10,11 the generation
of novel proteins, regulatory elements and genetic circuits,
repurposed for specific goals that are designed and engineered
without being constrained by overwhelming complexity of
natural cellular physiology.
Application of these principles to mammalian systems is
however hampered by several obstacles. Delivery of large
exogenous DNA in mammalian cells is often challenging.
Furthermore, mammalian cells are transfected with expression
constructs that are typically integrated randomly into the
genome.12 As a consequence, the expression of integrated
transgenes will be strongly influenced by the surrounding
chromatin state. Integration can cause dysregulation or
accidental disruption of endogenous genes and potentially
alter the behavior of the host cells.13 Subcellular compartments,
cellular differentiation, heterogeneity of individual cells, and
multicellular organization result in additional layers of
complexity. Predictability, delivery and prototyping of complex
genetic circuits are therefore challenging.
In this review, we will underline the potential advantages of
MACs used as a platform for loading and delivery of large
synthetic genetic constructs into mammalian cells. MACs might
provide a powerful tool for the application of synthetic biology
principles to mammalian system, due to their capability of
conferring the very high stability and transgene payload of a
native chromosome. The generation of MACs is still a complex
procedure and requires highly specialized knowledge and
methodologies for design, vector manipulation and construc-
tion. However, the reduced costs in de novo synthesis of
DNA,11 along with the recent advances in DNA assembly
technologies,10 have already paved the way for building of
entire chromosomes. The team from the J. Craig Venter
Institute (JCVI) was the first to synthesize and assemble a
complete bacterial genome.14 Recently the JCVI reported the
design and building a minimal bacterial genome of just 473
genes, but it contains 149 genes of unknown function.15 This
illustrates well the fact we can build a genome we do not fully
understand it. Similarly, a synthetic eukaryotic chromosome has
been completed and shown to be functional in a cell,16 and
work on a fully synthetic yeast genome is ongoing.17 We need
to bear in mind that this successful story is the culmination of
30 years of investigations on yeast chromosome biology since
the first eukaryotic artificial chromosomes was built in budding
yeast.18,19 This effort resulted in the identification of the key
determinants of chromosome generation and segregation in
this lower eukaryotic system. However, crucial differences exist
between bacterial artificial chromosome (BAC), yeast artificial
chromosome (YAC) and MAC formation, the most important
being the strong correlation between artificial chromosome
formation and epigenetic regulation, which plays a more
essential role in mammalian systems.19,20 Although plenty of
insights have been already gained on factors involved in the
dynamic of MAC formation, more understanding of the
principal events involved would provide new opportunities to
gain better control and simplify the making of new MACs.
Before describing the MACs and their potential applications,
it is important to understand why scalability, orthogonality and
predictability are important objectives that must be reached in
order to unleash the true potential of synthetic biology in
mammalian systems, and the obstacles ahead of this milestone.
Scalability. Gaining fine control over complex biological
processes, such as cellular differentiation and tissue develop-
ment, will likely require the design and implementation of
complex genetic circuits. A necessary step in programming
mammalian cell fate and responsiveness in a predictable
manner is therefore the construction of complex synthetic
gene networks, with a large number of regulatory elements, and
effectors. In mammalian cells, more complex regulatory layers
have been in part achieved by exploiting regulation of gene
expression not only at transcriptional level but also at
translational and post-translational level; such as employing
RNA devices for small molecules or protein-responsive switch
and controllable protein degradation.21,22 Furthermore, syn-
thetic intercellular communication systems can be designed to
interconnect cells engineered with different specialized
functions. Coordination of cell populations performing
complementary tasks may provide a solution to overcome the
limitations in single-cell rational engineering capacity, and
therefore enable the design of increasingly complex multi-
cellular gene networks.23 However, there is still a requirement
for the development of new regulatory layers that provide
control on multiple gene networks. Delivering large pieces
(hundreds of Kb to Mb) of exogenous DNA into the host cells
and ensuring its long-term stable functionality is another major
challenge associated with increased complexity.
Orthogonality, Characterization of Genetic Parts and
Predictability. Applying the engineering principle of stand-
ardization of parts and assembly in the construction of genetic
circuits, well-characterized genetic elements are assembled
together to build simple functional modules, such as genetic
switches,24 oscillators7 and cascades. These modules are then
combined with each other to generate more complex genetic
circuits. Single genetic parts or functional modules do not
change their essential properties once they are part of a larger
system, (ideally) independently of the cellular context, and this
modularity allows reliable prediction of the behavior of a
system from the interaction of its components.
Orthogonality refers to the notion that system components
can be varied independently without affecting the performance
of the other components and is essential for proper
characterization of genetic parts and in turn for predictability
of genetic circuits behavior. Having orthogonal systems that
operate independently of the cell’s natural machinery is also an
important feature that can be valuable to reduce risks of
undesirable off target effect in biomedical applications.
Orthogonality is often difficult to fully attain in biological
systems due to the complexity, especially in mammals.
Programmable synthetic transcription factors (sTFs), new
designer protein−protein interaction domains, subcellular
localization of proteins hub, generation of orthogonal
ribosome-mRNA pairs have been developed to generate
orthogonality between different genetic circuits and the
endogenous cellular processes.25−29 The availability of well-
characterized and orthogonal parts, however, is currently
limiting the engineering of complex circuits in mammalian
cells. Huge efforts have been made to standardize modularity in
prokaryotic systems, eukaryotic systems30 and generate
orthogonality,31,32 whereas standardization and characterization
of parts on a large scale is still missing in mammalian systems,
which still relies on a restricted library of orthogonal
components mainly imported from microbial systems.25
To ensure proper characterization of genetic parts interfer-
ence with the endogenous genome should be avoided when
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exogenous DNA is introduced. In mammalian cells location of
genes and their chromatin state are strongly connected and
mammalian genome is regulated in 3D.33 As a consequence, the
expression level of the same exogenous genes can vary
depending on the integration site and the chromatin
accessibility, as it is not only governed by its regulatory
elements such as promoters and enhancers, but also is strongly
influenced by the chromosomal context. The nature of the
integration site affects transcriptional levels and stability of
expression. This is called “position effect”.34 These context-
dependencies drastically limit the characterization, and there-
fore the predictability, of parts, transcription units and synthetic
circuits. Commonly used gene transfer methods, such as
retroviruses, lentiviruses and transposons, are limited in delivery
of specific copy numbers of the foreign DNA. The size of the
payload is also often limited and repetitive sequences should be
avoidedconditions difficult to fulfill for genetic circuits
comprising multiple transcription units.
Recently two major developments have enhanced our ability
to engineer the mammalian genome in a more efficient manner:
the CRISPR/Cas system and TALENs.35 The Clustered
Regularly Interspaced Short Palindromic Repeats (CRISPR)
Type II system or the use of Transcription Activator-Like
Effector Nucleases (TALENs) enables the production of site-
specific nucleases that are highly efficient. These can be used to
precisely manipulate the genome, including engineering of
targeted gene integration.35 Using these technologies, stable
chromosomal integration of genetic payloads into “safe harbor”
sites known to tolerate the integration of transgenes (e.g.,
AAVS1 for human and Rosa26 for mouse), can help achieve
long-term stable expression.36,37 In principle, transgenes
integrated into these genomic sites are stably expressed without
interfering with the activity of the endogenous genes.
Orthogonality is fulfilled and deleterious consequences are
avoided. However, it is arguable that no genome integration can
be defined as “safe” and no genomic safe harbor has yet been
fully validated.38 Newly integrated transgenic cassettes may still
influence surrounding loci and chromatin state, in undesirable
ways. Although intergenic regions are often chosen for targeted
transgene integration, noncoding genes are hard to detect, and
low-level transcription may commonly take place in these
regions.39 Larger changes may alter chromosome trans
interactions, chromosome 3D topologies,40 interchromosomal
crosstalk and the complex interplay of the genome with specific
features of nuclear architecture;41,42 such architectural control
through topology-associated domains is only now being
uncovered.
These may have unwanted effects, such as interactions
between transcriptional activators encoded in the vector and
the promoters of adjacent genes, particularly oncogenes and
micro-RNA genes.43 Reciprocally, locus specific long-range
interactions can have a profound effect on expression of
transgenes.44,45 Enhancer, insulators or other long-range
regulatory sequences are difficult to identify by simply looking
at the genome sequence itself. Cell differentiation is a highly
dynamic process with significant reconfiguration of chromoso-
mal topologies and epigenetic states, which we are only
beginning to fully appreciate; therefore, certain sites may be
more appropriate integration sites in specific tissues/lineages
but inappropriate in others: cellular context is the key driver.
It is because of these concerns that we would suggest that
there is a clear need for an alternative delivery system for large
chunks of exogenous DNA in mammalian cells. This system
should not interfere with the endogenous genome, thus
ensuring orthogonality. It should also provide a well-defined,
stable environment for loading of exogenous DNA and, as a
result, a more likely long-term stability of transgene expression.
Such a system would allow proper characterization of new
genetic circuits and prototyping. It should finally provide new
regulatory layers for the generation of more complex genetic
circuits.
■ EPISOMES AND MAMMALIAN ARTIFICIAL
CHROMOSOME (MAC) AS ORTHOGONAL
VECTORS
MACs can potentially provide an ideal platform for loading and
delivery of large complex genetic circuits in mammalian cells.
An artificial chromosome is complemented with components of
the chromosomes that are required for segregation during
mitosis and meiosis. An indispensable chromosomal element is
the centromere, which is required for the attachment of
chromosomes to the mitotic spindle and their segregation in
mitosis. Centromere proteins (CENPs) bind to the centro-
meric DNA and form the scaffold for the kinetochore. The
kinetochore mediates the connection between the centromere
and the spindle microtubles.20,46 Another essential component
for linear chromosomes is the telomere, which consists in short
repeat sequences present at the ends of the chromosomes.
Special proteins bind these sequences forming a cap that
prevent the chromosome ends from being recognized as
double-strand breaks, avoiding chromosome fusion. The linear
MAC comprises both centromere and telomeric ends. The
long-term stable maintenance of the MAC is ensured by the
presence of a functional centromere. The artificial chromosome
is therefore stably maintained as a single copy vector without
integration into the host chromosomes, allowing quantitative
control on number of transgene copies.47−49 MACs can hold
large amount of DNA with theoretically no upper size limit to
the DNA cloned.50,51 Clusters of genes encoding complex
pathways and complex synthetic circuits can be carried on a
single MAC. As described below, MACs, once constructed, can
be transferred among cell lines. Finally, lack of viral sequences
minimizes adverse host immunogenic responses.
As a consequence of its properties, the MAC therefore offers
an alternative orthogonal platform to accommodate large
genetic circuits and minimize undesired interference with
endogenous genes. Its genetic architecture is well characterized
and it has been shown to be mitotically stable in vitro for human
cells and both in vitro and in vivo in mouse cells.52−55 It has also
a system to prevent tumor formation.47
Episomal delivery vectorsi.e., extrachromosomally main-
tained sequences that can be multicopy, such as Epstein−Barr
virus (EBV) and scaffold/matrix attachment region (S/MAR)-
based vectorscan provide an alternative to MACs to
overcome the problem of position effects.56 However, episomal
vectors require components that ensure the replication and
maintenance of the exogenous DNA, avoiding the loss of the
vector after several rounds of cell division. This is usually done
providing the vector with viral sequences that function as origin
of replication.57 These origins of replication, however, require
the presence of viral proteins58 that are potentially immuno-
genic. Some episomes devoid of viral elements have been
developed,59 such as S/MARs-based vectors. S/MARs mediate
association with the nuclear matrix providing mitotic stability;60
episomal vectors harboring S/MAR cosegregate with the host
chromosome during mitosis.61 However, the episomal main-
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tenance of these vectors does not solve the problem of single
copy transgenes and does not exclude the eventuality of
aberrant chromosomal integration of the vector.
In the next paragraphs we discuss current strategies for MAC
construction, and how MAC can function not only as an
orthogonal vector, but alsodue to its intrinsic character-
isticshelp overcome the challenges of scalability and
predictability of genetic circuits in mammalian cells.
■ GENERATION OF MACS
MACs require a functional centromere essential to maintain
their nuclear location and to ensure their correct mitotic and
meiotic segregation; they can be linear or circular depending on
the method used for their generation. Most of the known
MACs have been built starting from human chromosome
elements therefore they are named as human artificial
chromosomes (HACs). Such HACs are mitotically stable in
Figure 1. “Top-down” approach for generation of 21HAC. The human chromosome 21 is first transferred from human cells to recombinant-
proficient chicken DT40 cells. The 21HAC is then generated by truncation of the p- and q- arms of the chromosome 21 and insertion of a loxP site
into the pericentromeric region of the q-arm. The HAC chromosome is then transferred to CHO (hprt−/−) cells where the desired transgene can
be cloned into the loxP site by Cre-mediated gene insertion with reconstitution of the HPRT gene. The HAC with the transgene is finally transferred
to the desired recipient cell via microcell-mediated chromosome transfer (MMCT).
Figure 2. “Bottom-up” approach for generation of alphoidtetO-HAC. Synthetic alphoid DNA array is generated by rolling circle amplification of the
alphoid tetO-alphoid hChr.17 dimer up to 5−10 Kb in size. The resulting alphoid array fragment is transferred to yeast cells and introduced in a
vector containing alphoid-specific hooks by TAR cloning. The resulting circular vector contains a mammalian selection marker (the Blastomicidin
resistance gene) and a BAC replicon that allows a YAC clone to be transferred into E. coli. Transfection of mammalian cells is followed by de novo
HAC formation. A loxP site is inserted into the alphoidtetO-HAC by homologous recombination into DT40 cells. The alphoidtetO-HAC is then
transferred into CHO (hprt−/−) cells where the desired transgene can be cloned into the loxP site by Cre-mediated gene insertion with
reconstitution of the HPRT gene. The HAC with the transgene is finally transferred to the desired recipient cell via MMCT. Following the
expression of a chromatin modifier gene fused with tet-R, the HAC is maintained in the presence of doxycyclin (Dox) or the HAC is destabilized in
the absence of Dox.
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human cells, in mouse and in chicken cells as well; very large
genomic DNA fragments have been introduce into mammalian
cells using HACs.62,63 HACs can also be transmitted through
the germlinethis has been shown for the murine and bovine
germline52,64−66providing evidence of the meiotic stability of
the HACs in vivo. However, the retention rates of HACs were
shown to be variable in mouse tissues.67 Recently Takiguchi et
al. reported the development of a mouse artificial chromosome
employing a native mouse centromere and showed that this
chromosome is stably maintained in a variety of tissues in
transgenic mice with high retention rate.55
Two main strategies are described, focusing on the most
advanced HACs generated to date (Figures 1−2). Further in
depth discussions of the methodologies used to build an
artificial chromosome have also been covered in several
excellent recent reviews.49,68
Top-down Approach. The top-down approach starts with
a natural human chromosome and seeks to strip it down and re-
engineer large regions. The chromosome is repeatedly
truncated into mini-chromosome through telomere-directed
chromosome truncation in homologous recombination-profi-
cient chicken DT40 cells.47,69 The resulting HAC, which is a
modified natural chromosome rather than a completely de novo
synthetic chromosome, can then be transferred into other cell
lines by microcell fusion. In the method known as microcell-
mediated chromosome transfer (MMCT), donor cells are
induced to multinucleate their chromosome and release them
into microcells, which can be fused to a recipient cell line.70
Minichromosomes have been created from human chromo-
somes X, Y and 14 using the top-down approach.69,71−75 The
most advanced top-down HAC is the 21HAC. It was generated
starting from the human chromosome 21 through several
rounds of the telomere-directed breakage removing almost all
the pericentromeric regions (Figure 1).47 The 21HAC vector
was physically characterized and no known endogenous genes
remained.
Bottom-up Approach. In the bottom-up approach, a de
novo HAC is generated transfecting eukaryotic cells with
synthetic alpha-satellite DNA. Human centromere DNA in
made of 171 bp AT-rich alpha-satellite monomers arranged into
tandem arrays that span 3−5 Mb. It is enriched with a 17-bp
binding motif for the recruitment of the centromere protein B
(CENP-B box), a protein involved in kinetochore assem-
bly.76−78 This alpha-satellite DNA has the potential for the de
novo centromere establishment in HACs. After being trans-
fected with 30−200 Kb alpha-DNA, by mechanisms not yet
fully understood, the cell recognizes the transgenic DNA as
centromeric seeding the deposition of specific protein and
epigenetic markers on the exogenous DNA. These modifica-
tions will lead to the generation of a fully active centromere,
thus converting the vector into an artificial chromosome.78 The
resulting HAC will be circular if the input DNA is cloned into a
BAC or linear when a YAC carrying telomeric sequences is
used as a vector to introduce the alphoid DNA in the target
cells79−82 (Figure 2). Alphoid DNA constructs can be
efficiently delivered into target cells using a method based on
herpex simplex virus type 1 (HSV-1) amplicons. This viral
vector can accommodate and deliver up to 152 kb of exogenous
DNA, overcoming the difficulties of introducing large alphoid
DNA constructs into the cells.83 The first “bottom-up”
approach for generation of HACs was developed in human
fibrosarcoma HT1080 cells.84 All the successive methods
developed for de novo generation of HACs were limited to
the only permissive cell line HT1080.49 This cell-type specific
barrier was broken when Ohzeki and collaborators identified
specific epigenetic marks associated with the alphoid DNA as
responsible for the restriction of de novo HAC formation to
HT1080 cells.85 They demonstrated that modification of the
chromatin state associated with the input alphoid DNA, is
required for the formation of stable centromere, and hence
HAC, in cell lines other than HT1080. De novo HAC
generation is now possible in a wide range of cell types,
including human embryonic stem (ES) cells.86
In the most advanced de novo constructed HAC, named
alphoidtetO-HAC, the synthetic alphoid DNA array contains
tetracycline operator (tetO) sequences. The advantage of
alphoidtetO-HAC is that it can be easily eliminated from
proliferating cells by expression of tet-repressor (tetR) fusion
proteins. These proteins bind to its centromeric tetO sequences
altering the chromatin and inactivating the kinetocore with
subsequent loss of the HAC.87 In a recent version, Kononenko
and colleagues placed a single copy of tTA-VP64 in the HAC,
avoiding the necessity of transfecting cells with potentially
mutagenic retrovirus or plasmids expressing TetR. tTA-VP64 is
constitutively expressed from the HAC, and after doxycycline
induced activation, it generates chromatin changes in the HAC
kinetochore that are not compatible with its function.88 The
alphoidtetO-HAC was physically characterized. It remains stable
over several months of propagation in host cells without any
structural rearrangements and was not seen to integrate into the
host chromosomes. The epigenetic status of the centromere
remains unaltered in time, even after multiple transfers from
one cell line to another.89 The alphoidtetO-HAC can be also
delivered into mouse ES cells where it is stable retained
throughout differentiation into somatic cell types of adult
mice.54
Loading of Genes into HACs. Targeted integration of
DNA into HAC is achieved using site-specific recombinase
technology. Acceptor sites for serine or tyrosine recombinases
are introduced in specific sites of the HAC by CRISPR/Cas9-
mediated DNA editing. Once the HAC has been modified with
the addition of acceptor sites it becomes an independent
loading platform where foreign DNA can be efficiently inserted
in vivo in single copy. The HAC, loaded with the desired
transgenes, if required, can then be transferred to the target cell
line. Yamaguchi et al. designed and generated a HAC vector
containing five acceptor sites recognized by five different
integrases.90 Using this system, up to five different genes can be
loaded onto the HAC. The limiting factor is that a different
selection marker is needed for each DNA fragment loaded.
Suzuki and colleagues developed a new method, which
overcomes the problem of the scarcity in selection markers.91
This simple method, called simultaneous or sequential
integration of multiple gene-loading vectors (SIM) system,
makes use of the gene trapping principle for the simultaneous
or sequential integration of multiple gene-loading vectors into a
HAC by reciprocal use of only two selection markers. The two
selection marker genes are recycled in each sequential gene
loading and deletion of selection marker genes is not required.
Each recombination and incorporation of a new cassette
switches the expression of selection marker genes by trapping
promoter activity of the previous drug resistance gene.
■ RAPID AND EFFICIENT PROTOTYPING
The site-specific recombination system used to load exogenous
DNA into the MAC provides a simple and efficient method for
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building of large synthetic circuits in vivo. The design of a new
loading system, such as the SIM system discussed before, will
open the possibility of sequential loading and if necessary
replacement of genetic circuits allowing the progressive
assembly of complex genetic circuits directly on the MAC.
The foreign DNA will be inserted into the same well-
characterized chromosomal context, kept as single copy DNA,
resulting in generation of isogenic stable cell lines, ensuring the
robust and fast prototyping of synthetic genetic networks is
possible. MACs can be also employed for high-throughput
screening of circuit libraries through integration of a multigene
payload library.
■ DESIGN AND IMPLEMENTATION OF NEW
REGULATORY LAYERS FOR GENE EXPRESSION
The MAC provides a platform for loading of complex genetic
circuits as it can accommodate foreign DNA of large size, but it
goes beyond it. The artificial chromosome as a vector offers
huge potentials for the implementation of more sophisticated
regulatory layers for expression of exogenous genes. We now
know that the level of complexity of an organism does not
relate to its number of genes. The human genome contains
approximately 25 000 protein-coding genes, only about five
times more than E. coli has, and represent less than 2% of the
total human genomic sequence.92 Pleiotropy, RNA splicing,
post-translational modifications, epigenetic and chromatin
remodeling provide additional parameters that contribute to
increased complexity. Although gene transcription is initiated at
promoters, the orchestration of transcription relies mostly on
surrounding intergenic regions, cis-regulatory regions (e.g.,
enhancers), and on the topological organization of the
genome.42,93,94 The eukaryotic genome is organized into
functionally and structurally distinct domains as a result of
intrachromosomal interactions and interactions with the
nuclear lamina.95−97 Within each domain, different epigenetic
modifications prevail, resulting in a demarcation of euchromatic
(transcriptionally active) and heterochromatic (transcription-
ally silenced) domains. Chromatin looping brings close distal
enhancer and promoters, enabling long-range transcriptional
regulation.98 By means of chromatin looping, a distal enhancer
is often engaged in contacts with multiple genes, likewise, many
genes form contacts with multiple distant enhancer, resulting in
coregulation of multigene networks. These interactions are
dynamic and change under different conditions or during cell
differentiation.42,99 Long-range transcriptional regulation by
distal enhancers is therefore an important mechanism that
drives the proper spatiotemporal regulation of gene expression
during development.
Epigenetic modifications, chromosomal domains and long-
range transcriptional regulation, are still not yet fully under-
stood at detailed mechanistic levels; nonetheless, these might
become important regulatory layers to consider when designing
complex genetic circuits. The MAC provides the perfect
orthogonal platform for the implementation of these regulatory
events. Once generated, the chromosome can be modified
within the cells. Site-specific recombination technology and
CRISPR/Cas9 system would provide an efficient way to
introduce user-defined sequences and to edit the DNA.100 The
artificial chromosome can therefore be regarded as an
engineering chassis to build upon. Different genes or genetic
circuits would be loaded at different locations within the
chromosome, without interfering with the endogenous genome.
The artificial chromosome DNA topology then becomes the
next level of transcriptional regulation. Insulator sequences
capable of recruiting the endogenous CTCF/cohesion complex
would favor the formation of chromatin domain boundaries
within the chromosome.95,97 The chromatin boundaries can be
then disrupted or modified targeting specific CTCF sites with
inducible synthetic DNA methylases/demethylases.101,102 The
chromatin state within each domain can be dynamically
modified, targeting the DNA with synthetic chromatin
editors.103 DNA-binding domains can be fused to protein
domains interacting with nuclear envelope proteins and used to
localize (and often silence) specific regions of the MAC in
proximity of the nuclear periphery.104 Coordinated spatial and
temporal expression of multiple genes in the HAC can be
achieved through chromatin looping. Inducible dimerization
factors, consisting of a DNA-binding domain fused to a
dimerization domain, can be employed to bring in close
proximity target sequences located at long distances within the
chromosome.105 Based on this strategy, in response to a specific
input, a synthetic enhancer would interact with multiple
promoters at once and vice versa.
■ LIMITATIONS OF MACS
Despite some of the advances, the engineering of MACs is still
quite difficult although several examples already exist.68 The
“top down” approach has been carried out only in
recombination-proficient chicken DT40 cells, however the
CRISPR-Cas9 system opens up an opportunity to attempt the
breakdown of endogenous chromosome also in other types of
cells and maybe to improve the process. The 21HAC derived
from human chromosome 21 has been physically characterized
and confirmed to be devoid of endogenous pericentromeric
regions.47 Other MACs generated using the “top down”
approach should be fully characterized as residual endogenous
material may result in genomic imbalances with possible
consequences on the phenotype.
The “bottom up” approach relies on the quite tedious
protocol of generating 30−200 Kb repetitive alpha-DNA and
cloning this into a BAC/YAC vector; the vector is then isolated
and delivered into the target cell. However, processing of BAC/
YAC vectors is very inefficient, as large circular DNA molecules
tend to randomly break and linearize during DNA transfection.
Using other method of delivery such as fusion of yeast
spheroblasts containing the YAC vector with mammalian target
cells may simplify the process.106 The HAC formation is always
accompanied by multimerization of the input alphoid DNA.89
Multimerization of the input DNA may therefore represent an
obligate step in MAC formation. These rearrangement events
result in structurally uncharacterized artificial chromosomes and
raise the issue on how to get better control on MAC formation
to avoid this problem. The process that leads to the generation
of a new centromere is not completely understood. In rare
instances, when a human chromosome loses its centromere due
to chromosome breakage, new functional centromeres, called
neocentromeres, can be generated on a nonalpha satellite
DNA.107 These events suggest that there is no absolute
requirement for any particular DNA sequence for the
generation of a centromere. Centromeric loci are rather defined
by specific epigenetic marks that are not specified by the
primary DNA sequence.19,20 MAC formation is therefore
strongly correlated with epigenetic regulation. Better under-
standing of the elusive epigenetic state of the centromere may
provide new means to turn normal chromatin into
centrochromatin through a more controllable process.
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Safe, streamlined and efficient procedures for MAC transfer
are still an important outstanding challenge for the future.
Although recent progress in the field have made possible the
targeting of different cell types, included fibroblasts,108 and
therefore possible the targeting of desired cells in vivo, the
method is still tedious and restricted to a few numbers of donor
cells suitable for microcell formation. Cloning and moving the
HACs via MMCT takes months and requires an expertise
rarely found in a standard laboratory. All these challenges call
for interdisciplinary teams to work together to address, and
together to push this field forward.
■ CONCLUSIONS
Our ability to effectively manipulate mammalian cells with fully
synthetic DNA elements at large scale would have myriad
possibilities for biotechnological and biomedical applications.109
The next-generation genetic circuits have the potential to
provide more precise and sophisticated control on gene
expression coupling sensing and delivery mechanisms and
opening up new exciting possibilities in generation of synthetic
multicellular networks. Circuits have already been designed for
diverse purposes, such as treating of metabolic disorder using
biosensor cells,110 or killing of cancer cells through cell death
promoting genetic sensor designed to detect specific sets of
cancer-associated signals111,112 or through chimeric antigen
receptor (CAR) T-cell therapies.113 The development of
synthetic biology in mammalian systems would also enable a
more systematic investigation on epigenetic mechanisms and
spatial regulation of gene expression. This in turn translates in
the possibility of higher control on induced pluripotent stem
cell (iPSC) differentiation to produce and engineer autologous
cells from patients114 for application in basic biology, disease
modeling, drug screening115 and new developments in
regenerative medicine. There is therefore great potentiality in
mammalian systems for engineering of new functions and
genetic devices, but also for gaining new insights into the
mechanisms operating in native cell systems.
In this promising avenue the MACs represent a new class of
promising vector for multiple applications. They bypass many
problems associated with existing viral and nonviral systems.
MACs have indefinite cloning capacities, copy number control,
long-term gene expression, and they are mitotically and
meiotically stable in the absence of selection. Potentially any
combination of genes can be cloned into the MAC and
transferred into a recipient target cell type. MACs have already
been used for gene function studies and are suitable vector for
gene therapy although further investigation is required to
evaluate efficiency and safety of MAC delivery, to cell cultured
in vitro but also in vivo using animal models.
MACs are also a potential platform for engineering of a more
sophisticated gene expression control in mammalian cells. In
combination with programmable synthetic transcription factors,
improved DNA synthesis and assembly, plus genome editing
technologies, MACs offer great opportunities for mammalian
synthetic biology. Complex genetic circuits can be designed and
built that impart spatial and temporal control over the
endogenous cellular genetic program. This strategy could
eventually prove to be a more efficient way to directly convert
fibroblasts into different cell types and to manipulate basic cell
behaviors such as proliferation, cell death, fusion, polarization,
locomotion, cell−cell adhesion, cell−cell communication, that
would allow ‘programmable morphogenesis’ for tissue gen-
eration. Exogenous biosynthetic pathways can be assembled
into the HAC to produce diverse compounds or complex
protein therapeutics. The HAC can be used to introduce
genetic constructs and pathways to test their effect on a certain
disease or drug treatment.
In summary, generation of MACs using simple methods of
manipulation and transfection holds great potential for
synthetic biology designs in mammalian cell lines and future
applications such as cell line generation, generation of
transgenic animals, human gene therapy and regenerative
medicine.
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